VAT1

Summary

VAT1 (vesicle amine transport 1, HGNC:16919) is a protein-coding gene on chromosome 17q21.31, encoding NADPH-dependent quinone oxidoreductase VAT1 (Q99536). Multifunctional protein with enzymatic and transport activities.

Synaptic vesicles are responsible for regulating the storage and release of neurotransmitters in the nerve terminal. The protein encoded by this gene is an abundant integral membrane protein of cholinergic synaptic vesicles and is thought to be involved in vesicular transport. It belongs to the quinone oxidoreductase subfamily of zinc-containing alcohol dehydrogenase proteins.

Source: NCBI Gene 10493 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 62 total
• Druggable target: yes
• MANE Select transcript: NM_006373

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16919
Approved symbol	VAT1
Name	vesicle amine transport 1
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	VATI, FLJ20230
Ensembl gene	ENSG00000108828
Ensembl biotype	protein_coding
OMIM	604631
Entrez	10493

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 nonsense_mediated_decay

ENST00000355653, ENST00000420567, ENST00000587062, ENST00000587147, ENST00000587173, ENST00000589709, ENST00000589828, ENST00000590924, ENST00000592388, ENST00000867390, ENST00000867391, ENST00000917596, ENST00000917597, ENST00000943217, ENST00000943218, ENST00000943219

RefSeq mRNA: 1 — MANE Select: NM_006373 NM_006373

CCDS: CCDS11451

Canonical transcript exons

ENST00000355653 — 6 exons

Exon	Start	End
ENSE00000727562	43016307	43016548
ENSE00001215708	43017841	43017930
ENSE00001215711	43018036	43018206
ENSE00001402203	43014607	43016144
ENSE00001405300	43021936	43022385
ENSE00003664601	43018592	43018799

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 190.2817 / max 1494.5993, expressed in 1826 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166210	165.1304	1825
166211	16.3745	1795
166209	6.0033	1389
166208	0.9842	604
166207	0.9581	582
166206	0.8311	560

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	99.20	gold quality
stromal cell of endometrium	CL:0002255	99.12	gold quality
right adrenal gland	UBERON:0001233	99.12	gold quality
left adrenal gland cortex	UBERON:0035825	99.08	gold quality
left adrenal gland	UBERON:0001234	99.04	gold quality
adrenal cortex	UBERON:0001235	99.02	gold quality
adrenal gland	UBERON:0002369	98.81	gold quality
lower esophagus mucosa	UBERON:0035834	98.73	gold quality
skin of leg	UBERON:0001511	98.60	gold quality
tendon of biceps brachii	UBERON:0008188	98.54	gold quality
endocervix	UBERON:0000458	98.29	gold quality
right lung	UBERON:0002167	98.27	gold quality
islet of Langerhans	UBERON:0000006	98.25	gold quality
left ovary	UBERON:0002119	98.23	gold quality
dorsal root ganglion	UBERON:0000044	98.12	gold quality
skin of abdomen	UBERON:0001416	98.12	gold quality
right ovary	UBERON:0002118	98.12	gold quality
mucosa of stomach	UBERON:0001199	98.09	gold quality
ganglionic eminence	UBERON:0004023	98.04	gold quality
ectocervix	UBERON:0012249	98.01	gold quality
zone of skin	UBERON:0000014	97.91	gold quality
omental fat pad	UBERON:0010414	97.90	gold quality
peritoneum	UBERON:0002358	97.87	gold quality
subcutaneous adipose tissue	UBERON:0002190	97.83	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.80	gold quality
smooth muscle tissue	UBERON:0001135	97.77	gold quality
olfactory bulb	UBERON:0002264	97.72	gold quality
gall bladder	UBERON:0002110	97.64	gold quality
body of uterus	UBERON:0009853	97.62	gold quality
tibial nerve	UBERON:0001323	97.59	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-93593	yes	551.47
E-CURD-122	yes	67.81
E-MTAB-8142	yes	17.29
E-MTAB-9067	yes	16.59
E-CURD-112	yes	6.18
E-MTAB-9801	yes	3.81
E-ENAD-20	no	991.87
E-MTAB-7303	no	900.96
E-MTAB-7037	no	857.03
E-MTAB-6386	no	832.69
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

124 targeting VAT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-182-5P	99.87	74.03	2589

Literature-anchored findings (GeneRIF, showing 7)

• VAT-1 is overexpressed in glioblastomas and functionally involved in glioma cell migration, representing a new component involved in glioma invasion (PMID:19508442)
• The role of phospholipase D in the transport of VAT1 to plasma membranes and in phosphatidic acid metabolism in neutrophils is reported. (PMID:20858461)
• We demonstrate that VAT-1 is a novel pathogenic factor in benign prostatic hyperplasia associated with cell proliferation. (PMID:21394740)
• Structural basis for interorganelle phospholipid transport mediated by VAT-1. (PMID:32005660)
• Structural insights into vesicle amine transport-1 (VAT-1) as a member of the NADPH-dependent quinone oxidoreductase family. (PMID:33483563)
• Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. (PMID:33576871)
• Identification and Characterization of Synaptic Vesicle Membrane Protein VAT-1 Homolog as a New Catechin-Binding Protein. (PMID:38403661)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	vat1	ENSDARG00000056481
mus_musculus	Vat1	ENSMUSG00000034993
rattus_norvegicus	Vat1	ENSRNOG00000020684
drosophila_melanogaster	Drat	FBGN0033188
caenorhabditis_elegans		WBGENE00010790
caenorhabditis_elegans		WBGENE00010791
caenorhabditis_elegans		WBGENE00014096
caenorhabditis_elegans		WBGENE00017060

Paralogs (17): PTGR1 (ENSG00000106853), TP53I3 (ENSG00000115129), MECR (ENSG00000116353), CRYZ (ENSG00000116791), RTN4IP1 (ENSG00000130347), PTGR2 (ENSG00000140043), SORD (ENSG00000140263), VAT1L (ENSG00000171724), ADH6 (ENSG00000172955), PTGR3 (ENSG00000180011), ADH1A (ENSG00000187758), ADH7 (ENSG00000196344), ADH1B (ENSG00000196616), ADH5 (ENSG00000197894), ADH4 (ENSG00000198099), CRYZL1 (ENSG00000205758), ADH1C (ENSG00000248144)

Protein

Protein identifiers

NADPH-dependent quinone oxidoreductase VAT1 — Q99536 (reviewed: Q99536)

Alternative names: Mitofusin-binding protein, Synaptic vesicle membrane protein VAT-1 homolog, Vesicle amine transport 1

All UniProt accessions (7): Q99536, K7EJM4, K7EM19, K7ENX2, K7ER81, K7ERT7, K7ESA3

UniProt curated annotations — full annotation on UniProt →

Function. Multifunctional protein with enzymatic and transport activities. Probable NADPH-dependent quinone oxidoreductase which physiological substrates and function are unclear. Alternatively, has also been suggested to mediate the transfer of negatively charged phospholipids including phosphatidic acid (PA), phosphatidylserine (PS) and phosphatidylglycerol (PG) between endoplasmic reticulum and mitochondrial membranes. Could regulate mitochondrial fusion through its interaction with mitofusins.

Subunit / interactions. Forms homodimers and homotetramers. Interacts with MFN1 and MFN2; regulates mitochondrial membranes dynamic.

Subcellular location. Cytoplasm. Cytosol. Mitochondrion outer membrane.

Tissue specificity. Expressed in brain. Also expressed in glioblastoma cells.

Induction. Up-regulation in basal keratinocytes is Ca(2+)-dependent.

Similarity. Belongs to the zinc-containing alcohol dehydrogenase family. Quinone oxidoreductase subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q99536-1	1	yes
Q99536-2	2
Q99536-3	3

RefSeq proteins (1): NP_006364* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002364	Quin_OxRdtase/zeta-crystal_CS	Conserved_site
IPR011032	GroES-like_sf	Homologous_superfamily
IPR013154	ADH-like_N	Domain
IPR020843	ER	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR052100	VAT1	Family

Pfam: PF08240, PF13602

Catalyzed reactions (Rhea), 6 shown:

• 2 a quinone + NADPH + H(+) = 2 a 1,4-benzosemiquinone + NADP(+) (RHEA:14269)
• a 1,2-diacyl-sn-glycero-3-phosphate(in) = a 1,2-diacyl-sn-glycero-3-phosphate(out) (RHEA:36435)
• a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-sn-glycero-3-phospho-L-serine(out) (RHEA:38663)
• a 1,2-diacyl-sn-glycero-3-phospho-(1’-sn-glycerol)(in) = a 1,2-diacyl-sn-glycero-3-phospho-(1’-sn-glycerol)(out) (RHEA:39743)
• 2 1,2-naphthoquinone + NADPH + H(+) = 2 1,2-naphthosemiquinone + NADP(+) (RHEA:85243)
• 2 9,10-phenanthroquinone + NADPH + H(+) = 2 9,10-phenanthrosemiquinone + NADP(+) (RHEA:85247)

UniProt features (75 total): strand 20, helix 16, binding site 13, modified residue 6, sequence conflict 5, mutagenesis site 4, turn 4, region of interest 2, splice variant 2, initiator methionine 1, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6K9Y	X-RAY DIFFRACTION	2.2
6LII	X-RAY DIFFRACTION	2.3
6LHR	X-RAY DIFFRACTION	2.62

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99536-F1	90.74	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (13): 240; 241; 285; 288; 291; 326; 328; 379; 90; 200; 201; 222 …

Post-translational modifications (6): 2, 2, 18, 27, 35, 44

Mutagenesis-validated functional residues (4):

Position	Phenotype
100	decreased lipid transfer activity in vitro; when associated with n-330.
172	decreased lipid transfer activity in vitro.
225	increased lipid transfer activity in vitro.
330	decreased lipid transfer activity in vitro; when associated with n-100.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 288 (showing top): RNGTGGGC_UNKNOWN, AP1_01, REACTOME_INNATE_IMMUNE_SYSTEM, TGCGCANK_UNKNOWN, KAAB_FAILED_HEART_ATRIUM_DN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOCC_SECRETORY_GRANULE, ENK_UV_RESPONSE_KERATINOCYTE_UP, AREB6_03, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GOZGIT_ESR1_TARGETS_DN, AREB6_01, AP4_Q6, CAGCTG_AP4_Q5, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP

GO Biological Process (2): negative regulation of mitochondrial fusion (GO:0010637), intermembrane phospholipid transfer (GO:0120010)

GO Molecular Function (5): zinc ion binding (GO:0008270), NADPH dehydrogenase (quinone) activity (GO:0008753), phospholipid transfer activity (GO:0120014), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (8): extracellular region (GO:0005576), cytoplasm (GO:0005737), mitochondrial outer membrane (GO:0005741), cytosol (GO:0005829), azurophil granule lumen (GO:0035578), extracellular exosome (GO:0070062), mitochondrion (GO:0005739), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
phospholipid transport	2
cytoplasm	2
mitochondrial fusion	1
regulation of mitochondrial fusion	1
negative regulation of organelle organization	1
negative regulation of developmental process	1
intermembrane lipid transfer	1
transition metal ion binding	1
NAD(P)H dehydrogenase (quinone) activity	1
NADPH dehydrogenase activity	1
phospholipid binding	1
lipid transfer activity	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
mitochondrial membrane	1
organelle outer membrane	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1
extracellular vesicle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1408 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
VAT1	TLN1	Q9Y490	518
VAT1	UBLCP1	Q8WVY7	412
VAT1	FA2H	Q7L5A8	349
VAT1	ODAD4	Q96NG3	339
VAT1	AIFM2	Q9BRQ8	324
VAT1	SCP2	P22307	320
VAT1	CZIB	Q9NWV4	317
VAT1	LAP3	P28838	316
VAT1	CHCHD3	Q9NX63	312
VAT1	NTHL1	P78549	306
VAT1	SH3GLB2	Q9NR46	304
VAT1	SAMM50	Q9Y512	290
VAT1	SLC38A10	Q9HBR0	289
VAT1	SCCPDH	Q8NBX0	288
VAT1	QSOX2	Q6ZRP7	284

IntAct

52 interactions, top by confidence:

A	B	Type	Score
PHLPP2	NHERF1	psi-mi:“MI:0914”(association)	0.760
PLP1	VAT1	psi-mi:“MI:0915”(physical association)	0.560
GMFG	PRUNE1	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400
SDC1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
PCNA	VAT1	psi-mi:“MI:0915”(physical association)	0.370
	ESYT2	psi-mi:“MI:0914”(association)	0.350
MAPK6		psi-mi:“MI:0914”(association)	0.350
ORF72	CDK2	psi-mi:“MI:0914”(association)	0.350
DLD	NFKBIE	psi-mi:“MI:0914”(association)	0.350
SOD1	NPEPPSL1	psi-mi:“MI:0914”(association)	0.350
MAPT	MEX3A	psi-mi:“MI:0914”(association)	0.350
PAK1		psi-mi:“MI:0914”(association)	0.350
PE25	ACSL4	psi-mi:“MI:0914”(association)	0.350
ZDHHC5	HACD3	psi-mi:“MI:0914”(association)	0.350
ZDHHC5	IGKV2D-24	psi-mi:“MI:0914”(association)	0.350
H2AX	ANXA6	psi-mi:“MI:0914”(association)	0.350
RIN3		psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
SMIM26	METTL15	psi-mi:“MI:0914”(association)	0.350
SAR1B	UBA6	psi-mi:“MI:0914”(association)	0.350
BDH2	CKS2	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
LETM2	EIF3CL	psi-mi:“MI:0914”(association)	0.350
MTCH2	IPO5	psi-mi:“MI:0914”(association)	0.350

BioGRID (176): VAT1 (Affinity Capture-MS), VAT1 (Proximity Label-MS), VAT1 (Affinity Capture-RNA), VAT1 (Affinity Capture-MS), VAT1 (Affinity Capture-MS), VAT1 (Affinity Capture-MS), VAT1 (Affinity Capture-MS), VAT1 (Affinity Capture-MS), VAT1 (Affinity Capture-MS), VAT1 (Proximity Label-MS), VAT1 (Proximity Label-MS), VAT1 (Proximity Label-MS), VAT1 (Proximity Label-MS), VAT1 (Proximity Label-MS), VAT1 (Proximity Label-MS)

ESM2 similar proteins: A0A6N3IN21, A3KCL7, A6QQF5, B0BNC9, O35678, O75911, O77769, O88876, O97764, P00333, P05336, P11415, P14673, P14674, P14675, P17648, P28032, P47199, P50336, Q08257, Q0MVN8, Q0P5F9, Q28452, Q28GQ2, Q2R8Z5, Q3MIE4, Q3UGR5, Q3UNZ8, Q5BJJ5, Q5R4B4, Q5R4S7, Q60HD5, Q62465, Q6AYR6, Q6AYT0, Q75ZX4, Q80TB8, Q8LEB2, Q8R1Q9, Q8R238

Diamond homologs: A0A068ABB7, A0A075TRC0, A0A089QRB9, A0A0B5KU17, A0A0F7U103, A0A0S6XH49, A0A0U5GK88, A0A1B3PEI8, A0A1L7U3D7, A0A1L9WQM9, A0A1R3RGK0, A0A1V6PAA5, A0A1W5T1T1, A0A2I2F262, A0A345BJP0, A0A3G1DJH7, A0A3G9GQ29, A0A8K1AWG4, A1CFL8, A2R6H1, A7RK30, B4ER97, B6HNK3, B8NYX0, D4AU31, E0D203, E5A7D9, E9F8M3, G0R6S8, G1XU04, G3J453, G3J9P0, G3XMD1, G3XNF4, G4NEB1, I1RLA7, K3VA96, N4WHE3, O31782, O31784

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 71 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transcriptional regulation of granulopoiesis	5	13.3×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

2534 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:43018612:A:T	V192D	0.997
17:43018760:A:G	W143R	0.997
17:43018760:A:T	W143R	0.997
17:43022053:G:C	F90L	0.997
17:43022053:G:T	F90L	0.997
17:43022055:A:G	F90L	0.997
17:43016548:C:T	G286E	0.996
17:43018146:C:T	G219E	0.996
17:43022056:G:C	N89K	0.996
17:43022056:G:T	N89K	0.996
17:43016500:G:T	A302D	0.995
17:43017858:C:A	G280V	0.995
17:43016134:G:T	A370D	0.994
17:43017858:C:T	G280D	0.994
17:43017918:A:T	V260D	0.994
17:43021983:C:G	G114R	0.994
17:43021985:T:A	E113V	0.994
17:43022064:C:A	G87W	0.994
17:43018141:C:G	A221P	0.993
17:43021982:C:T	G114D	0.993
17:43021991:C:T	G111D	0.993
17:43016097:C:A	K382N	0.992
17:43016097:C:G	K382N	0.992
17:43016431:C:T	G325D	0.992
17:43018127:C:A	K225N	0.992
17:43018127:C:G	K225N	0.992
17:43021976:C:T	G116D	0.992
17:43021986:C:T	E113K	0.992
17:43022063:C:T	G87E	0.992
17:43017859:C:G	G280R	0.991

dbSNP variants (sampled 300 via entrez): RS1000057655 (17:43014740 T>A), RS1000529574 (17:43014481 T>C), RS1000581878 (17:43014940 T>C), RS1000760443 (17:43020483 T>TGCATA), RS1000862974 (17:43014982 A>G), RS1001088094 (17:43020637 G>A), RS1001296394 (17:43023162 G>A), RS1001392224 (17:43022726 T>TA), RS1001523273 (17:43017963 T>A), RS1001810013 (17:43016956 G>T), RS1002382287 (17:43021550 C>T), RS1002532642 (17:43019469 G>C,T), RS1002689940 (17:43021901 G>A,C), RS1002880362 (17:43022453 G>C), RS1003066028 (17:43019169 A>C,G)

Disease associations

OMIM: gene MIM:604631 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4802015 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 5 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.35	IC50	4480	nM	CHEMBL4214264
5.34	IC50	4540	nM	CHEMBL4214264
5.10	Kd	7964	nM	CHEMBL3752910
5.10	ED50	7964	nM	CHEMBL3752910

PubChem BioAssay actives

3 with measured affinity, of 7 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one	1716424: Covalent binding affinity to VAT1 at Cys residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide ACGLNFADLMAR incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11-isopropyl-10,13,17-trioxo-3,6-dioxa-9,12,16-triazaoctadecyl)-6-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanamide and heavy thiol probe 4 for 1 hr under dark conditions followed by tryptic digestion for overnight and measured by discovery ABPP based nano LC-MS/MS analysis	ic50	4.4800	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149757: Binding affinity to human VAT1 incubated for 45 mins by Kinobead based pull down assay	kd	7.9638	uM

CTD chemical–gene interactions

71 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, increases expression, affects cotreatment, decreases expression	4
Valproic Acid	affects expression, increases expression	4
bisphenol F	increases expression, affects cotreatment, decreases expression	2
sodium arsenite	decreases expression, increases expression	2
cobaltous chloride	increases expression	2
Dexamethasone	decreases expression, affects cotreatment	2
Smoke	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	increases expression	2
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
benzo(b)fluoranthene	increases expression	1
pyrogallol 1,3-dimethyl ether	increases expression, decreases expression, affects cotreatment, affects localization	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
ochratoxin A	decreases expression	1
1,2,5,6-dibenzanthracene	increases expression	1
coumarin	increases phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
CGP 52608	affects binding, increases reaction	1
JP8 aviation fuel	affects expression	1
chloropicrin	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
jinfukang	increases expression	1
(+)-JQ1 compound	increases expression	1
bisphenol AF	increases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4721799	Binding	Covalent binding affinity to VAT1 at Cys86 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment f	Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. — ACS Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3L5	Abcam HEK293T VAT1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.